Pulmonx to Report Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022

Rhea-AI Summary

Pulmonx Corporation (Nasdaq: LUNG) will release its financial results for Q4 and full year 2021 on February 23, 2022, after market close. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET for discussion and analysis of the results. Investors can participate via phone or through a live webcast available on Pulmonx's investor website. Pulmonx is recognized for its minimally invasive solutions for severe lung disease, including the Zephyr® Endobronchial Valve, which has treated over 25,000 patients globally.

Positive

• Zephyr Valve has treated over 25,000 patients worldwide.
• Product is commercialized in over 25 countries.
• FDA pre-market approval received, designated as a breakthrough device.

Negative

• None.

REDWOOD CITY, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2021 after the close of trading on Wednesday, February 23, 2022. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.

Investors interested in listening to the conference call may do so by dialing (833) 614-1518 for domestic callers or (270) 823-1072 for international callers, followed by Conference ID: 8494407. A live and archived webcast of the event will be available on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.

About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for severe lung disease. Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, with over 100,000 valves used to treat more than 25,000 patients. For more information on the Zephyr Valves, please visit https://uspatients.pulmonx.com/. For more information on the company, please visit www.Pulmonx.com.

Pulmonx®, Chartis®, StratX®, and Zephyr® are registered trademarks of Pulmonx Corporation.

Contact
Brian Johnston
Gilmartin Group
investors@pulmonx.com

FAQ

When will Pulmonx release its financial results for 2021?

Pulmonx will release its financial results for Q4 and full year 2021 on February 23, 2022.

What time is the Pulmonx conference call scheduled for?

The conference call is scheduled for 1:30 p.m. PT / 4:30 p.m. ET on February 23, 2022.

How can I listen to the Pulmonx conference call?

Investors can listen by dialing (833) 614-1518 for domestic calls or (270) 823-1072 for international calls, using Conference ID: 8494407.

What products does Pulmonx offer for lung disease treatment?

Pulmonx offers the Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, and StratX® Lung Analysis Platform for treating severe lung disease.